Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Free Mirikizumab · 1 trial · 1 indication
Cmax of Mirikizumab is reported.
AUC \[0-∞\] of Mirikizumab is reported.
AUC \[0 to tlast\] of Mirikizumab is reported.
| Arm | Type | Description |
|---|---|---|
| 200 mg Mirikizumab (Test) | EXPERIMENTAL | Participants received 200 mg mirikizumab test formulation, 1 × 2-mL SC injections of 100 mg/mL citrate-free mirikizumab administered into arm/thigh/abdomen on day 1. |
| 200 mg Mirikizumab (Reference) | EXPERIMENTAL | Participants received 200 milligrams (mg) mirikizumab reference formulation, 2 × 1-milliliter (mL) subcutaneous (SC) injections of 100 mg/mL citrate-free mirikizumab administered into arm/thigh/abdomen on day 1. |
| Name | Type | Description |
|---|---|---|
| Citrate-Free Mirikizumab | DRUG | Administered SC |
Inclusion Criteria: Type of participant and disease characteristics 1. Overtly healthy males and females as determined by medical evaluation including: * Medical history, * Physical examination, * Clinical laboratory tests, * Electrocardiogram (ECG), * Vital signs Note: partici...
Free Mirikizumab is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development for use in healthy individuals, as part of a bioequivalence study. The drug is being developed by Eli Lilly and Company.
Free Mirikizumab is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical development for use in healthy participants.
Free Mirikizumab is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials. The drug is being studied in healthy participants as part of a bioequivalence study.
Free Mirikizumab is associated with one completed clinical trial, NCT06475729, titled 'A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants.' This Phase 1 trial enrolled 498 healthy participants in the United States and has been completed.
Yes, Free Mirikizumab is also known as LY3074828. The clinical trial NCT06475729, which studies Free Mirikizumab, is titled 'A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants,' confirming that these names refer to the same drug.